Donna L. Topping's research while affiliated with Duke University and other places

... Significant reductions in FN incidence for pegfilgrastim primary prophylaxis versus no pegfilgrastim primary prophylaxis were also seen in observational studies of patients with breast cancer (4 % vs 30 %) and in patients with various tumour types (odds ratio [95 % confidence interval (CI)]= 0.49 [0.34-0.68]) [48,41]. ...

... Nevertheless, high Treg TIL quantities without CD8+ T cells were not associated with better survival in ER-positive breast cancer patients [63]. Based on the studies to date, further research is needed to clarify the role of Treg cells in tumoral immune response and their interaction with other cell populations present in the tumor [64]. Thus, future studies on their prognostic role in patient samples are necessary to finally determine the clinical importance of Treg cell assessment. ...

... Preliminary data from the phase I clinical trial of LY3484356 demonstrated encouraging results at lower doses (400 mg, orally once daily), however, higher doses were associated with progressive disease (Table 1) [93]. Additionally, a significant number of patients experienced diarrhea (22%) and nausea (35%) which will likely limit the use of LY3484356 in the adjuvant setting in combination with CDK4/6 inhibitors, which demonstrate significant gastrointestinal side effects as monotherapies [93,94]. Preliminary data from the Phase I/II clinical trial of amcenestrant showed exceptional efficacy in patients with advanced ER+ breast cancer, although only 56.4% of patients had received prior endocrine therapy and only 5.4% had received prior CDK4/6 inhibitors (Table 1) [95]. ...